
ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder
One of the hottest areas of immunology involves immune reset, therapies that give the immune system the opportunity for a fresh start. - Promising outcome after faecal transplant for nut allergy – small US study – Juta MedicalBrief
And that's exciting,” said Cathryn Nagler, an immunology researcher at the University of Chicago in Illinois. Before taking part in the study, … - Immune 'reprogramming' could protect poultry from deadly diseases without antibiotics
This development, published today, Aug. 12, in The Journal of Immunology, offers a major step forward in sustainable farming and the global fight … - Alfasigma gains arthritis drug, access to new markets with M&A play | Fierce Pharma
In a deal announced this week, Alfasigma spent an undisclosed sum to continue its global expansion in immunology. - Dietmar Berger on Gilead's Strategy: Beyond HIV, Building Durable Oncology and …
… immunology franchises. In a wide-ranging interview on The Bio Report, Berger refused to set percentage targets for the future revenue mix …

